Sangamo Biosciences (SGMO) was Downgraded by Piper Jaffray to ” Neutral”. Earlier the firm had a rating of “Overweight ” on the company shares. Piper Jaffray advised their investors in a research report released on Oct 19, 2016.
On the company’s financial health, Sangamo Biosciences reported $-0.38 EPS for the quarter, missing the analyst consensus estimate by $ -0.14 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.24. The company had revenue of $3.70 million for the quarter, compared to analysts expectations of $5.55 million. The company’s revenue was down -56.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.17 EPS.
Sangamo Biosciences closed down -0.16 points or -3.95% at $3.89 with 10,01,539 shares getting traded on Friday. Post opening the session at $4.09, the shares hit an intraday low of $3.89 and an intraday high of $4.17 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 17, 2015, Edward O Ii Lanphier (President & CEO) sold 25,000 shares at $10.43 per share price. According to the SEC, on Jul 14, 2015, Henry Ward Wolff (Exec VP & CFO) sold 12,000 shares at $10.00 per share price. On Jun 9, 2015, Dale G Ando (VP, Therapeutic Dev. & CMO) sold 15,000 shares at $12.29 per share price, according to the Form-4 filing with the securities and exchange commission.
Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Company’s lead ZFP Therapeutic SB-728-T a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Company’s clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.